Immuneering (IMRX)
NASDAQ:IMRX
IMRX Stock Chart & Stats
$5.52
-$0.24(-10.17%)
At close: 4:00 PM EST
$5.52
-$0.24(-10.17%)
Day’s Range― - ―
52-Week Range$1.10 - $10.08
Previous CloseN/A
Volume3.55M
Average Volume (3M)985.82K
Market Cap
$356.88M
Enterprise Value$75.57M
Total Cash (Recent Filing)$172.83M
Total Debt (Recent Filing)$3.82M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
May 12, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding64,652,920
10 Day Avg. Volume569,476
30 Day Avg. Volume985,815
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-6.37
Enterprise Value/Market Cap0.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-95.57
Enterprise Value/Ebitda-1.29
Forecast
1Y Price Target
$17.00Price Target Upside207.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.19
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Survival DataUpdated survival results from an expanded atebimetinib plus chemotherapy cohort could clarify whether the therapy provides a meaningful overall survival benefit compared with standard treatment.
Financial LiquidityReported cash reserves sufficient to support operations for multiple years reduce near‑term financing risk and enable continued clinical development without immediate capital raises.
Regulatory And Late‑stage DevelopmentProceeding with the pivotal MAPKeeper Phase 3 trial after alignment with regulatory authorities reinforces a clear regulatory pathway toward potential approval and commercialization.
Bears Say
Competitive DifferentiationUncertainty about how atebimetinib meaningfully differs from a competing therapy has reduced investor confidence and placed downward pressure on the stock.
Data‑timing And Market Volatility RiskMarket reaction could remain volatile until additional survival data are released, creating downside risk if updates are delayed or outcomes are inconclusive.
Dependence On Overall Survival AdvantageSimilar progression‑free results to a competitor mean that a demonstrated overall survival advantage will be necessary for the therapy to achieve a clear clinical and commercial edge.
Immuneering News
IMRX FAQ
What was Immuneering’s price range in the past 12 months?
Immuneering lowest stock price was $1.10 and its highest was $10.08 in the past 12 months.
What is Immuneering’s market cap?
Immuneering’s market cap is $356.88M.
When is Immuneering’s upcoming earnings report date?
Immuneering’s upcoming earnings report date is May 12, 2026 which is in 30 days.
How were Immuneering’s earnings last quarter?
Immuneering released its earnings results on Mar 06, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.312 by $0.132.
Is Immuneering overvalued?
According to Wall Street analysts Immuneering’s price is currently Undervalued.
Does Immuneering pay dividends?
Immuneering does not currently pay dividends.
What is Immuneering’s EPS estimate?
Immuneering’s EPS estimate is -0.28.
How many shares outstanding does Immuneering have?
Immuneering has 64,652,920 shares outstanding.
What happened to Immuneering’s price movement after its last earnings report?
Immuneering reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.312. Following the earnings report the stock price went up 7.028%.
Which hedge fund is a major shareholder of Immuneering?
Currently, no hedge funds are holding shares in IMRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immuneering Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (207.97% Upside)
$17.00 (207.97% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 31.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $234.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
345.16%
12-Months-Change
Fundamentals
Return on Equity
-43.33%
Trailing 12-Months
Asset Growth
340.08%
Trailing 12-Months
Company Description
Immuneering
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
IMRX Stock 12 Month Forecast
Average Price Target
$17.00
▲(207.97% Upside)
Technical Analysis
Ownership Overview
9.49% Insiders
15.53% Mutual Funds
13.89% Other Institutional Investors
52.64% Public Companies and
Individual Investors